Global marketing of cholesterol-lowering drugs as therapy.
Pharmaceutical marketing services (PMS) are a key component of pharmaceutical companies' marketing strategies in that they create links between the pharmaceutical company and the physician. They are is also a link between physician and patients locally and globally. PMS discussed in this paper provide various services from tangible to intangible products in order to increase the physicians and pharmacists prescribing activities of their treatment modalities. Given the high cost of recruiting, training, and supporting PMS global marketing efforts, it is important for PMS channels to understand the significance of pharmaceutical multinational companies to ascribe to prescription drug services provided in Thailand. This created the unique marketing environment for the pharmaceutical companies. This study examines whether there is a gap in the existing cholesterol-lowering medication prescribed by physicians in Thailand and the newly introduced brand to the U.S. market. The degree of the new product adoption is analyzed through physician prescription frequency and records. Results of the study indicate there is significant improvement in the health conditions of the users of the new cholesterol medication among Thailand patients. Physicians in Thailand were, however, faced with competing brands in the market due to aggressiveness of advertising and promotion by multinational pharmaceutical marketing and manufacturers Associations. Perceived value and benefit to users were significant outcome of the study. More diagnostic and prescriptive research is recommended to cover Southeast Asia and other parts of the developing countries.
Elimimian
Jonathan U
JU
College of Business, Albany State University, Albany, GA 31705, USA.
Gilmore
James M
JM
Singletary
Tony J
TJ
D004345:Drug Industry; D011307:Drug Prescriptions; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D038622:Internationality; D040541:Marketing; D008485:Medical Audit; D013785:Thailand; D016896:Treatment Outcome
D000960:Hypolipidemic Agents